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development, immunity, inflammation, and cancer progression. Two cell death mechanisms,
apoptosis and necroptosis, are dependent on the formation of distinct multi-protein complexes
including the DISC, Apoptosome, Piddosome and Necrosome following the induction of cell death
by specific stimuli. The role of several of these key multi-protein signalling platforms, namely the
DISC, TNFR1 complex I/II, the Necrosome and Ripoptosome, in mediating these pathways will be
discussed, as well as the open questions and potential therapeutic benefits of understanding their
underlying mechanisms.
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Multi-protein complexes: Initiators of cell death
There are numerous ways in which a cell can die; however, the
most well-known cell death mechanisms are that of apoptosis and
necrosis. Apoptosis is a highly regulated process dependent on the
formation of multi-protein complexes initiated by specific stimuli,
which permit activation of caspases leading to cell disassembly
and death. Necrosis, conversely, has long been considered to occur
in a non-regulated fashion, however the discovery of necrotic
morphology following treatment of cells with death ligands, in the
absence of caspase activation, lead to the concept of necroptosis or
programmed necrosis [1]. Like apoptosis, necroptosis involves the
formation of multi-protein complexes which initiate signalling
pathways, ultimately resulting in cellular demise. Thus, it is nowFig. 1 – Death receptor signalling: apoptosis or cell survival? Trime
various adapter proteins through homophilic DD interactions. Sign
and/or cFLIP. This can induce direct activation of caspase-8 leading
Alternatively, a secondary cytoplasmic complex can form containin
recruits FADD and caspase-8 to the receptor; RIP1 may also be recru
from the membrane or form a secondary complex containing casp
competent to promote cell survival via activation of NFκB. By contr
TRAF2, and cIAP1/2 to form the membrane-associated, complex I, l
signalling to apoptosis can be initiated via the formation of the cyto
and TRADD or caspase-8, FADD and RIP1, respectively.clear that protein complexes play a crucial role in cell death
signalling. By dissecting these complexes we can not only learn
how cell death is regulated but also how these key cell death
signalling platforms can be targeted for therapeutic benefit.Death Receptor Signalling to Apoptosis: a ‘Complex’
decision
The CD95/TRAIL DISC
The ‘death-inducing signalling complex’ or DISC is responsible for
transducing death ligand stimulation of the death receptors CD95,
TRAIL-R1 or TRAIL-R2 to apoptosis (Fig. 1). Death receptors are a
subset of the TNF receptor superfamily that possess a death domain
(DD) in their cytoplasmic tail, which enables recruitment ofrization of CD95, TNFR1 or TRAIL-R1/2 initiates recruitment of
alling from CD95 results in recruitment of FADD, caspase-8/10,
to apoptosis via cleavage of downstream substrates.
g FLIP (L, S or R isoforms). Activation of TRAIL-R1/2 likewise
ited [73]. Like CD95, TRAIL-R1/2 can directly activate apoptosis
ase-8, FADD, RIP1, TRADD, TRAF2 and NEMO which are
ast, activation of TNFR1 results in recruitment of TRADD, RIP1,
eading to activation of NFκB cell survival. Alternatively,
plasmic complexes, IIA and IIB, which contain caspase-8, FADD
1271E X P E R I M E N T A L C E L L R E S E A R C H 3 1 8 ( 2 0 1 2 ) 1 2 6 9 – 1 2 7 7additional proteins and consequently assembly of a multi-protein
complex. Formation of the DISC can be regulated by post-
translational modification of the receptors, resulting in improved
ligand binding, receptor aggregation and/or recruitment to lipid
rafts. These modifications can take the form of phosphorylation, S-
glutathionylation, O-glycosylation [2] or palmitoylation (reviewed
in [3]).
TRAIL signalling is complicated by the existence of two
signalling competent receptors, TRAIL-R1 and TRAIL-R2. These
receptors can induce apoptosis independently, although TRAIL-R2
requires extensive cross-linking for full activity [4,5]. When co-
expressed, TRAIL-R1/TRAIL-R2 can co-operate to induce cell death
via the formation of heterocomplexes [6,7]; however, their co-
expression does not signify equal contribution as TRAIL-R2 has
been identified as the predominant receptor in some cancers [8],
whilst in other tumour types TRAIL-R1 predominates [9,10].
Once stimulated, death receptors recruit the adaptor protein
FADD via a homotypic interaction between the DDs present in
both proteins. Since ligands and receptors of the TNF superfamily
tend to self-associate into trimers [11,12], it was presumed that
trimeric receptors would subsequently recruit three molecules of
FADD. However, recent structural reports on the interaction
between the isolated DDs of CD95 and FADD have indicated that
these domains predominantly assemble into a complex at a ratio
of 5:5, with a small number of complexes formed with between 5
and 7 of each DD [13,14]. This is in line with the concept of a
‘honeycomb’ DISC structure where adjacent complexes are
‘stitched’ together by either CD95 [15] and/or FADD [16]. Whilst
the structure of the CD95-DD:FADD-DD interaction provides
valuable insight into these DD interactions, caution should be
exercised when extrapolating this structure to the native DISC
since it cannot account for any steric constraints imposed by
either the cell surface membrane or the additional domains
present in full-length proteins.
Following its recruitment to the receptor, FADD uses its death
effector domain (DED) to recruit tandem DED proteins (proteins
containing two DEDs at their N-termini such as procaspase-8/-10 or
c-FLIP) to the DISC. Based on structural modelling it has been
suggested that these proteins are recruited to the complex via DED2
[17,18]; in support of this, mutation of residues F122/L123 in DED2
of procaspase-8 prevented its association with FADD, although this
observation was based on co-immunoprecipitation of overex-
pressed proteins [17]. However, this does not explain why earlier
studies reported a role for both DED1 and DED2 in efficient
recruitment of procaspase-8 to the DISC [19]. This conundrum
could be explained by recent data from our group suggesting that
DED2 alone is not responsible for procaspase-8 recruitment to the
DISC (Dickens et al., in press). Therefore, it is essential that further
work on the structure of the DISC be undertaken, utilising full length
proteins, in order to fully understand how this complex assembles
and how factors that modulate this critical step might impinge on
downstream signalling.
As well as inducing the formation of the membrane-associated
DISC, stimulation of CD95 and TRAIL receptors can also induce the
formation of secondary cytoplasmic signalling complexes [20,21]
(Fig. 1). The CD95 secondary complex is formed following CD95
ligation at the cell membrane; upon CD95 DISC formation this
secondary complex, composed of only FADD, c-FLIPL/S/R and
caspase-8, is subsequently released and potentially enhances
apoptosis by amplifying caspase activation [21]. The TRAIL-induced secondary complex, composed of FADD, caspase-8, RIP1,
TRAF-2, NEMO, and possibly TRADD, activates kinase pathways
which increase chemokine production, suggesting that the role of
this secondary complex may be to promote macrophage phago-
cytosis of apoptotic cells [20].
It is now clear that defects in death receptor signalling
molecules can have detrimental effects on the immune system as
well as wide ranging implications in human disease. In particular,
CD95-dependent apoptosis plays a clear role in the elimination of
excess T-cells during the immune response. Autoimmune lym-
phoproliferative syndrome (ALPS) is a human disorder character-
ized by chronic lymphoproliferation, autoimmune symptoms and
an increased risk of malignancy, and bears striking similarities to
the lpr (lymphoproliferation) and gld (generalised lymphoproli-
ferative disease) strains of mice that have defects in those genes
encoding CD95 and CD95L, respectively. Similarly, the majority of
ALPS patients contain germline or somatic mutations in CD95,
with some cases containing mutations in genes encoding CD95L or
caspase-10. As a consequence, ALPS patients exhibit impaired or
defective CD95-mediated apoptosis, leading to the dysregulation
of T-cell homeostasis and the accumulation of proliferating
lymphocytes. In addition, two cases of patients with mutations
in caspase-8 have been reported. However, although these
patients exhibit phenotypes similar to ALPS, in contrast to other
ALPS patients, these cases exhibited defects in lymphocyte and
natural killer cell activation leading to immunodeficiency and
hence recurrent bacterial and viral infection (reviewed in [22]).
TNFR1-induced apoptosis
Whilst stimulation of CD95 and TRAIL-R1/2 primarily results in
the induction of apoptosis, stimulation of TNF receptor 1 (TNFR1),
on the other hand, chiefly induces pro-inflammatory and
immune-stimulatory activity through the JNK, p38-MAPK and
NFκB pathways (reviewed in [23]) (Fig. 1). Instead of recruiting
FADD, TNFR1 initially recruits the alternative adaptor molecule
TRADDwhich in turn recruits TRAF2, RIP1 [24,25], and cIAP1 and 2
to form TNFR1 complex I (reviewed in [26]). Formation of this
complex may rely on the RNA binding molecule Sam68 which has
been demonstrated to be important in facilitating the recruitment
of RIP and in the retention of TRAF2 and cIAP1 [27]. Ubiquitination
plays a crucial role in signalling activated by TNFR1; TRAF2 and
cIAP1/2 attach K63-linked ubiquitin chains to RIP1, which pro-
motes efficient NFκB activation. Furthermore, cIAP-mediated
polyubiquitin chains also recruit the linear ubiquitination chain
assembly complex (LUBAC), which stabilises TNFR1 complex I via
attachment of linear ubiquitin chains to NEMO, and possibly other
components of the complex (reviewed in [28]).
TNFR1-induced apoptosis is solely activated upon formation of
caspase-containing secondary complexes, namely complex IIA or
IIB, which are negatively regulated by cFLIP and cIAPs [29],
respectively. Complex IIA may form either a cytoplasmic complex,
which assembles when TRADD is released from the membrane-
bound TNFR1 [24], or alternatively remain associated with TNFR1
in endocytic vesicles following receptor internalisation [30].
Dissociation of RIP1 and TRAF2 from TRADD, releases TRADD
enabling it to recruit FADD (via DD interactions), which in turn
recruits procaspase-8. Since NFκB can regulate cFLIPL expression,
activation of NFκB by complex I prevents apoptotic signalling
arising from complex IIA, whilst a low activity of complex I
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[24] (Fig. 1).
Complex IIB is TRADD-independent and forms following co-
treatment with TNFα and Smac mimetics (which inhibit IAPs).
Formation of complex IIB requires deubiquitination of RIP1 by the
deubiquitinating enzyme CYLD [29] and release of RIP1 from
complex I; RIP1 can then directly oligomerise with FADD and
thereby recruit procaspase-8 to induce apoptosis.
Initiator caspases — a ‘two-step’ activation model
FollowingDISC assembly, it is essential that caspases be activated for
apoptosis to proceed. Accordingly, the main purpose of the multi-
protein DISC or TNFR1 complex II is to produce an environment
conducive for the activation of the initiator caspases, procaspase-
8 or -10. Once activated, these caspases can cleave downstream
substrates, such as procaspase-3 or Bid, resulting in cell death.
It has long been recognised that caspases require dimerization
for full activity, however the role of autoproteolysis in initiator
caspase activation has, until recently, been unclear. Originally,
self-cleavage was considered non-essential for initiator caspase
activity [31,32] since in vitro studies indicated that the active site
could form in the absence of cleavage [33]. In contrast, in vivo
mouse studies demonstrated that cleavage of procaspase-8 was
essential for CD95-induced apoptosis [34]. A likely explanation for
this discrepancy was the use of truncated (ΔDED) variants of
caspase-8 in vitro, which were not activated in the context of the
DISC. This issue was addressed in a study from our group where
the DISC was reconstituted in vitro using the intracellular death
domain of CD95 and full length recombinant FADD and
procaspase-8 [35]. We demonstrated that caspase-8 is activated
at the DISC via a two-step mechanism. In step one, dimerization of
procaspase-8 results in a low level activation directed against a
limited substrate repertoire, i.e. only substrates bound into the
DISC; whilst in step two, cleavage of the inter-catalytic subunit
linker results in a fully activated DISC with increased catalytic
activity and a broader substrate repertoire, thereby enhancing
signalling to apoptosis [35]. In support of this two-step model, a
subsequent study independently confirmed the requirement for
both dimerization and cleavage in the activation of procaspase-
8 [36].
Interestingly, procaspase-8 activation may also be modulated
by post-translational modifications. Phosphorylation at tyrosine-
380 by c-Src inhibits caspase-8 autocatalytic cleavage between the
large and small subunits, suppressing CD95-induced apoptosis
[37], whilst polyubiquitination of procaspase-8 by Cullin-3 was
reported in lung tumour cells to promote aggregation and full
caspase-8 activation [38].
The role of cFLIP
cFLIP is a well-documented regulator of caspase activity at the
DISC and TNFR1 complex IIA, although the absolute effect of cFLIP
is dependent on both the amount and particular isoform recruited.
Alternative splicing generates three isoforms of cFLIP (cFLIPL,
cFLIPS and cFLIPR) which all contain two DEDs. In addition, cFLIPL
possesses p20 and p12 caspase-like domains but lacks the
catalytic site [39]. The short isoforms of cFLIP (cFLIPS and cFLIPR)
can be recruited to the DISC via their DEDs and inhibit death
receptor-mediated apoptosis by preventing caspase-8 activationand processing [40,41]. cFLIPL is also recruited to the DISC or
TNFR1 complex IIA via its DEDs, however the effect of cFLIPL
recruitment is more complex than for the short isoforms and is
dependent on both its expression level as well as the extent of
death receptor stimulation [42]. At physiological levels, cFLIPL
heterodimerizes with procaspase-8 at the DISC, aids its activation
and promotes apoptosis [43]. In contrast, when highly expressed,
cFLIPL like cFLIPS, blocks caspase-8-mediated apoptosis via the
DISC or complex IIA [24,43–45]; however, unlike cFLIPS, this is not
achieved by inhibition of procaspase-8 processing. Instead, when
overexpressed, cFLIPL is able to allosterically activate caspase-
8 permitting partial processing of procaspase-8 to its p43/p10
cleavage fragments; in the absence of full processing, caspase-8,
which remains associated within the complex, can only cleave
local substrates (itself and RIP) and does not induce apoptosis
[40,46,47]. Intriguingly, recent findings suggest that caspase-8-
cFLIPL heterodimers may instead function to protect cells from
necrosis (see later and [48]).Multi-protein Complexes as Initiators of Necroptosis
Programmed necrosis, or ‘necroptosis’ [1], occurs in the absence of
the canonical apoptotic markers and is often tightly regulated.
Until recently the mechanism underlying how necroptosis was
executed and/or regulated was poorly understood, however
recent advances have begun to shed light on the complexes
which drive this alternative form of cell death (Fig. 2).
A role for key apoptotic regulators in limiting necroptosis
There has long been evidence of a role for caspase-8, FADD and
cFLIP in T-lymphocyte activation and proliferation as well as in
development; however, it was unclear how these traditionally
apoptotic molecules could also function in pro-inflammatory and
cell survival pathways. It has now become apparent that these
non-apoptotic functions are largely mediated by limiting the
induction of necroptosis (Fig. 2a).
FADD and caspase-8 are known to be required for the survival
of antigen-activated T cells since ablation of either protein results
in cell death via RIP1-dependent necroptosis [49,50]. Further
studies have also revealed a primary role for RIP3 in promoting
necroptosis in antigen-stimulated T cells lacking catalytically
active caspase-8 and that caspase-8 possibly protects from
necroptosis by cleaving RIP1 and/or RIP3 [51,52]. Thus, it is
evident that caspase-8 activity is essential for controlling RIP1/
RIP3-dependent necroptosis in activated T cells. In addition, recent
work has identified a role for FADD and caspase-8 in suppressing
RIP3-mediated necroptosis in both intestinal epithelial cells and
epidermal keratinocytes, thereby protecting against chronic
inflammation [53–55]. Moreover, in animal models, mice deficient
in FADD, caspase-8 or cFLIP die in utero at approximately day 10.5
displaying both cardiac malformations and haemorrhage. Intrigu-
ingly, unlike caspase-8 deficient mice, Casp8−/−Ripk3−/−mice are
viable and develop into fertile adults, however by 4 months they
develop abnormal T-cell accumulation similar to that observed in
CD95-deficienct (lpr) mice. A further study independently found
that RIP1 deficiency is sufficient to rescue the embryonic lethality
and T-cell proliferation defect observed in FADD−/− mice
Fig. 2 – Overview of necroptosis-inducing complexes. (a) Protein complexes involved in proliferation and development; during
development RIP1–RIP3-mediated necroptosis is inhibited by caspase-8–FLIPL heterodimers in a complex with FADD. Ablation/
inhibition of FADD, caspase-8, or FLIP results in RIP1/RIP3-dependent necrosis and embryonic or T-cell death. (b) Death
receptor-induced necroptosis is triggered when caspases are inhibited and apoptosis is blocked. RIP1 and RIP3 form a complex with
FADD and caspase-8 (TRADD may also be a component of this complex); both RIP1 and RIP3 are phosphorylated and signal to
necroptosis. (c) The ripoptosome complex is assembled upon genotoxic stress and IAP depletion and comprises, caspase-8, FADD
and RIP1; the exact signalling outcome is modulated by cFLIP isoforms.
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mice is embryonic lethal, in humans a defect in caspase-8 results
in impaired lymphocyte and natural killer cell activation (as
discussed previously). In a recent study by Chen et al., mice with a
T cell-specific disruption in caspase-8 were generated and
exhibited a reduction in T-cell numbers, proliferation and immune
response, similar to the above ALPS-related disorder [57].
Importantly, although the phenotype was rescued when RIP1/RIP3 were also eliminated, these mice displayed progressive
abnormal T-cell accumulation, symptoms typical of lpr-like
lymphoproliferative disease. This study established that RIP3-
dependent necroptosis eliminates T-cells when caspase-8 is
absent or non-functional, whereas concurrent ablation of both
the apoptotic and necroptotic pathways results in lpr disease.
Caspase-8 is therefore essential for maintaining T-cell homeosta-
sis, immune responses and preventing immunodeficiency and has
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Taken together, the animal models described to date suggest that
both FADD and caspase-8 may promote survival during develop-
ment by preventing RIP3 and RIP1-dependent necroptosis.
The mechanism by which caspase-8 prevents RIP3-mediated
necroptosis was recently dissected in vitro by Oberst et al. who
demonstrated that it occurs via formation of an ‘inhibitory’
caspase-8-FLIPL heterodimer [48]. However, how this heterodimer
inhibits RIP1–RIP3 signalling to necroptosis is currently unclear. It
may proceed either via targeted degradation or caspase-8-
mediated cleavage of RIP1 and/or RIP3; cleavage of CYLD or
other, as yet unidentified, mechanisms. Indeed, CYLD was
identified in a genome wide screen for regulators of necroptosis
[58] and has recently been shown to be cleaved by caspase-8 [59].
Furthermore, expression of a non-cleavable mutant of CYLD in
Cyld−/− MEFs rapidly induced necrosis, thereby linking CYLD
cleavage by caspase-8 to protection against necrosis [59]. Thus, it
would be intriguing to investigate whether CYLD is also a
substrate for caspase-8-FLIPL heterodimers and whether CYLD is
part of a multi-protein complex with RIP1–RIP3.
The ‘Necrosome’
Although the nature of the complex that drives developmental
necroptosis remains elusive, the complex involved in inducing
necroptosis downstream of death receptors is well defined
(Fig. 2b). When apoptotic cell death is blocked by caspase
inhibitors (e.g., zVAD or viral proteins), many cells can alter their
mode of cell death to necroptosis and RIP1 and RIP3 play a critical
role in this switch [60,61]. As described above, TNFR1 can activate
NF-κB or apoptosis depending on the ubiquitination status of RIP1
and subsequent formation of complex II. However, following
TNFα stimulation, under conditions where caspase activity is
blocked, apoptosis is inhibited and instead the cell favours
necrotic death. In this scenario, RIP1 interacts with RIP3 via
RHIM (RIP homotypic interaction motif) domains [62]; since
caspase-8 activity is blocked, RIP3 forms a stable ‘complex II’ with
RIP1, FADD and caspase-8 transforming it into a necroptosis-
inducing complex termed the ‘necrosome’. It is currently unclear
whether the adaptor molecule TRADD is also part of this complex,
although it may be present in some cell types. In contrast, the
kinase activities of both RIP1 and RIP3 are obligatory for
necrosome formation [1,63,64] as both mutual and autopho-
sphorylation of RIP1 and RIP3 within the complex are required for
activation of the downstream necrotic signalling pathway [61,63].
Intriguingly, in the absence of active caspases, CD95 and TRAIL-R1/
R2 can also signal to necroptosis, however unlike TNFR1-induced
necroptosis, there is an absolute requirement for FADD in necrotic
cell death induced by these receptors [60]. Currently, the exact
mechanism by which necroptosis is executed remains unclear,
however it has been suggested that it may in part involve
increased ROS production [63] and/or modulation of energy
metabolism by RIP1–RIP3 [65] (reviewed in [66]).
The ‘Ripoptosome’
Recently, an additional necroptosis inducing complex termed the
‘ripoptosome’ has been identified [67,68] (Fig. 2c). The core
components of this complex, namely RIP1, FADD and caspase-8,
are ubiquitinated by IAPs under normal conditions, resulting intheir proteosomal degradation and suppression of ripoptosome
formation. However, following exposure to Smac mimetics or
genotoxic stress, IAPs are down-regulated resulting in spontane-
ous formation of the ripoptosome and triggering of caspase-8-
mediated apoptosis or caspase-independent necroptosis. The
exact signalling outcome initiated following ripoptosome forma-
tion is regulated by cFLIP isoforms. Formation of caspase-
8 homodimers within the complex results in full catalytic activity
and thus apoptosis. In contrast, formation of caspase-8-cFLIPL
heterodimers instead results in limited catalytic activity which
although not sufficient to trigger apoptosis is however able to
cleave RIP1. This in turn leads to ripoptosome disassembly and cell
survival [67,68]. Finally, when heterodimerization of caspase-
8 with cFLIPS predominates, caspase-8 activation and RIP1
cleavage are prevented, thereby promoting ripoptosome forma-
tion; in this situation apoptosis is blocked and the mode of cell
death is instead switched to necroptosis [68].
Interestingly, it has been indicated that the ripoptosome can be
recruited to other signalling platforms, such as the Toll-like
receptor-3 (via the adaptor molecule TRIF), and therefore could
aid in the initiation of necroptosis following immune or pro-
inflammatory signals [68]. Indeed RIPK-mediated necroptosis
induced by the pathogen recognition receptor family (such as
the Toll-like receptors) is an important mechanism for cellular
defence against viral infections [69]. Notably, viruses often express
anti-apoptotic proteins that prevent caspase-8 recruitment or
activation at the DISC to prolong cell viability and to facilitate viral
replication. Thus, necroptosis may act as a back-up mechanism to
kill infected cells in which apoptosis is blocked, and in this
capacity boost the innate immune system.Concluding Remarks
Whilst apoptosis had previously been thought of as the principal
programmed or regulated form of cell death, the significance of
alternative death pathways has recently come to light and begun
to change this perception. Recent findings concerning the
underlying mechanisms of both necroptosis and apoptosis
demonstrate that regulated necrosis can no longer be regarded
as inconsequential but instead highlight its importance in normal
development, immunity, inflammation and cancer progression.
Furthermore, it has become increasingly clear that the deciding
factor between these two modes of cell death is centred around
the activity of the pro-apoptotic proteins, caspase-8, FLIPL and
FADD as well as the kinases, RIP1 and RIP3. Indeed it has been
suggested by some that the dominant function of caspase-8 is to
convey a pro-survival signal that suppresses necroptosis rather
than its more canonical function in apoptosis.
A greater understanding of the switch between the two means
of programmed cell death alongside increased knowledge of the
exact mechanisms underlying necroptosis, could well result in
major therapeutic advances in a number of diseases by potentially
identifying new clinical targets. Furthermore, since many malig-
nancies show an altered propensity or resistance to undergo
apoptosis it may be that alternative therapies could be developed
which promote cancer regression by initiating a necroptotic
response and thus reduce tumour cell yield [70]. However, this
could also potentially stimulate an inflammatory and/or
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the blood stream; the challenge therefore lies in promoting
necroptosis whilst simultaneously preventing unwanted side-
effects. Equally, the inhibition of necroptosis could help rein in the
inflammatory response found in many chronic conditions or
brought about by certain drug combinations; likewise preventing
RIP3-mediated programmed necrosis could be crucial in preventing
inflammatory conditions such as Crohns disease, irritable bowel
syndrome and chronic skin inflammatory diseases; thus,
necrostatin-like drugs could potentially be used as possible future
therapeutic agents for a range of inflammatory and degenerative
disorders. Indeed, necrostatin-1 has already shown promising
therapeutic potential in ischemic myocardial, retinal and brain
injury by inhibiting RIP1 activity [1,71,72]. Moreover, the control of
necroptosis is important to the pathogenesis of a number of viruses,
such as murine cytomegalovirus (MCMV); this implies that
therapeutic intervention in some viral diseases could also benefit
from a better understanding of necroptosis in these situations.
Whilst the explosion of recent papers has started to unravel
the mysteries surrounding necroptosis a number of questions
remain unanswered. For example, the mechanism by which the
‘FADD–FLIPL–caspase-8’ complex prevents RIPK-dependent ne-
crosis during development is not fully understood. However, the
recent finding that caspase-8-mediated cleavage and degradation
of CYLD disables the necrosis machinery is an important entry
point into answering this question [59]. Several other questions
also arise, such as how is this complex formed? For example, does
FADD act as a platform to bring RIP1/RIP3 into close proximity
with the caspase-8-FLIPL heterodimer? Is the complex spontane-
ously assembled, and if so under what conditions?
It is clear that further progress is needed in order to fully
understand how apoptosis and necroptosis are tightly regulated
and how in some contexts these two processes are closely
interconnected. However, with the current elevated interest in
this exciting and rapidly moving field, the answers to these
important questions will surely be forthcoming.Acknowledgments
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